11/9/2021 8:34:24 AM
VTv Therapeutics Q2 Loss Per Share $0.02 Vs Loss $0.01 Last Year
10/20/2021 9:03:14 AM
VTv Therapeutics Appoints Deepa Prasad As President And CEO
10/12/2021 7:59:49 AM
VTv Therapeutics Says Mechanistic Study Of TTP399 In Patients With Type 1 Diabetes Primary Endpoint
9/24/2021 7:15:49 AM
VTv Therapeutics Announces Results Of MAD Study Of HPP737 In Healthy Adults
9/16/2020 7:36:35 AM
VTv Therapeutics To Present Addnl Positive Clinical Study Results From Phase 2 Simplici-T1 Study Of TTP399
7/27/2020 7:42:08 AM
VTv Therapeutics To Present Additional Clinical Data From STEADFAST Study Of Azeliragon
5/27/2020 7:37:31 AM
VTv Therapeutics To Present Two Late-breaking Abstracts Reinforcing Potential Of TTP399